Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab Combination for High-Risk Neuroblastoma Consolidation
NCT04909515Phase 2Withdrawn
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Dec 2021
- Primary completion
- Jun 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of naxitamab in neuroblastoma, sponsored by Y-mAbs Therapeutics, Inc.. Planned start Dec 2021; status: withdrawn.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04909515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04909515.